
Royalty Pharma plc: shareholders and insiders
Price
$68.67
November 18, 2026Market cap $29.5B
What Ploutos Investor adds for Royalty Pharma
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$116M
5 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $89M by 4 people
- 2025: no buys, sold $28M by 3 people
- 2026: no buys, sold $89M by 4 people
- Nov 17, 2026Christopher HiteEVP & Chairman, PartneringKind10b5-1
- Nov 17, 2026Terrance P. CoyneEVP & CFOKind10b5-1
- Nov 17, 2026Terrance P. CoyneEVP & CFOKind10b5-1
- Nov 16, 2026Terrance P. CoyneEVP & CFOKind10b5-1
- Nov 16, 2026Terrance P. CoyneEVP & CFOKind10b5-1
- Nov 16, 2026Terrance P. CoyneEVP & CFOKind10b5-1
- Nov 16, 2026Marshall UristEVP, Research & InvestmentsKind10b5-1
- Nov 16, 2026Marshall UristEVP, Research & InvestmentsKind10b5-1
- Nov 6, 2026Terrance P. CoyneEVP & CFOKind
- Nov 6, 2026Terrance P. CoyneEVP & CFOKind
- Nov 6, 2026Marshall UristEVP, Research & InvestmentsKind
- Nov 4, 2026Terrance P. CoyneEVP & CFOKind
- Nov 4, 2026Marshall UristEVP, Research & InvestmentsKind
- Nov 4, 2026Pablo G. LegorretaCEO, Chairman of the BoardKind
- Nov 4, 2026Christopher HiteEVP & Chairman, PartneringKind
- Oct 5, 2026Marshall UristEVP, Research & InvestmentsKind10b5-1
- Sep 30, 2026Bonnie L BasslerDirectorKind
- Sep 28, 2026Marshall UristEVP, Research & InvestmentsKind10b5-1
- Sep 22, 2026Christopher HiteEVP & Chairman, PartneringKind10b5-1
- Sep 22, 2026Christopher HiteEVP & Chairman, PartneringKind10b5-1
- Aug 19, 2026Christopher HiteEVP & Chairman, PartneringKind10b5-1
- Aug 18, 2026Christopher HiteEVP & Chairman, PartneringKind10b5-1
- Aug 13, 2026Terrance P. CoyneEVP & CFOKind10b5-1
- Aug 13, 2026Terrance P. CoyneEVP & CFOKind10b5-1
- Aug 5, 2026Pablo G. LegorretaCEO, Chairman of the BoardKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Christopher HiteEVP & Chairman, Partnering | 10b5-1 | 100.0K | $68.15 | $6.8M | Form 4 |
| Nov 17, 2026 | Terrance P. CoyneEVP & CFO | 10b5-1 | 14.8K | $68.30 | $1.0M | Form 4 |
| Nov 17, 2026 | Terrance P. CoyneEVP & CFO | 10b5-1 | 9,835 | $68.30 | $671.8K | Form 4 |
| Nov 16, 2026 | Terrance P. CoyneEVP & CFO | 10b5-1 | 135.2K | $68.87 | $9.3M | Form 4 |
| Nov 16, 2026 | Terrance P. CoyneEVP & CFO | 10b5-1 | 90.2K | $68.87 | $6.2M | Form 4 |
| Nov 16, 2026 | Terrance P. CoyneEVP & CFO | 10b5-1 | 7,122 | $68.87 | $490.5K | Form 4 |
| Nov 16, 2026 | Marshall UristEVP, Research & Investments | 10b5-1 | 23.6K | $69.47 | $1.6M | Form 4 |
| Nov 16, 2026 | Marshall UristEVP, Research & Investments | 10b5-1 | 1,408 | $69.99 | $98.6K | Form 4 |
| Nov 6, 2026 | Terrance P. CoyneEVP & CFO | 150.0K | – | – | Form 4 | |
| Nov 6, 2026 | Terrance P. CoyneEVP & CFO | 100.0K | – | – | Form 4 | |
| Nov 6, 2026 | Marshall UristEVP, Research & Investments | 150.0K | – | – | Form 4 | |
| Nov 4, 2026 | Terrance P. CoyneEVP & CFO | 7,122 | – | – | Form 4 | |
| Nov 4, 2026 | Marshall UristEVP, Research & Investments | 5,341 | – | – | Form 4 | |
| Nov 4, 2026 | Pablo G. LegorretaCEO, Chairman of the Board | 42.2K | – | – | Form 4 | |
| Nov 4, 2026 | Christopher HiteEVP & Chairman, Partnering | 7,122 | – | – | Form 4 | |
| Oct 5, 2026 | Marshall UristEVP, Research & Investments | 10b5-1 | 4,126 | $57.10 | $235.6K | Form 4 |
| Sep 30, 2026 | Bonnie L BasslerDirector | 642 | $58.41 | $37.5K | Form 4 | |
| Sep 28, 2026 | Marshall UristEVP, Research & Investments | 10b5-1 | 4,126 | $57.88 | $238.8K | Form 4 |
| Sep 22, 2026 | Christopher HiteEVP & Chairman, Partnering | 10b5-1 | 96.1K | $58.51 | $5.6M | Form 4 |
| Sep 22, 2026 | Christopher HiteEVP & Chairman, Partnering | 10b5-1 | 3,927 | $58.93 | $231.4K | Form 4 |
| Aug 19, 2026 | Christopher HiteEVP & Chairman, Partnering | 10b5-1 | 16.8K | – | – | Form 4 |
| Aug 18, 2026 | Christopher HiteEVP & Chairman, Partnering | 10b5-1 | 100.0K | $59.97 | $6.0M | Form 4 |
| Aug 13, 2026 | Terrance P. CoyneEVP & CFO | 10b5-1 | 9,230 | $58.59 | $540.8K | Form 4 |
| Aug 13, 2026 | Terrance P. CoyneEVP & CFO | 10b5-1 | 1,772 | $59.14 | $104.8K | Form 4 |
| Aug 5, 2026 | Pablo G. LegorretaCEO, Chairman of the Board | 65.2K | – | – | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 28, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by RPRX's officers and directors from 2002 up to November 18, 2025, 24 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 19 more, back to 2002
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Legorreta G. Pablowith 1 more personClass A ordinary shares, par value $0.0001 per shareShare of class18.7%
- Morgan Stanleywith 1 more personClass A Ordinary SharesShare of class9.20%
- Capital International InvestorsShare of class8.80%
- BlackRock, Inc.AShare of class5.70%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Legorreta G. Pablowith 1 more personClass A ordinary shares, par value $0.0001 per share | 18.7% | 102M | Aug 17, 20262 filings since May 23, 2025 | 13D/A | |
| Morgan Stanleywith 1 more personClass A Ordinary Shares | 9.20% | 38.91M | Aug 5, 2025 | 13G/A | |
| Capital International Investors | 8.80% | 37.77M | May 14, 20264 filings since Aug 13, 2025 | 13G/A | |
| BlackRock, Inc.A | 5.70% | 25.45M | Feb 4, 2025 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Legorreta G. Pablo18.7%From the filing of May 23, 2025
The information in Items 3, 5 and 6 of this Schedule 13D is incorporated herein by reference. Each Reporting Person acquired the securities described in this Schedule 13D for investment purposes and intends to review its investments in the Issuer on a continuing basis. Any actions a Reporting Person might undertake may be made at any time and from time to time without prior notice and may be informed by such Reporting Person's review of numerous factors, including but not limited to an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels and availability of the Issuer's securities or other financial instruments; general market, industry…
From the filing of May 23, 2025
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- AQR CapitalIn the quarter+14%
- Bridgewater (Dalio)In the quarter
- Renaissance TechnologiesIn the quarter-69%
- Citadel Advisors (Griffin)In the quarter-49%
- D.E. ShawIn the quarter-53%
- Point72 (Cohen)In the quarter-78%
- Millennium Mgmt (Englander)In the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| AQR Capital | 4.31M | +14% | $241M | 0.08% |
| Bridgewater (Dalio) | 219.7K | $12M | 0.05% | |
| Renaissance Technologies | 591.1K | -69% | $35M | 0.05% |
| Citadel Advisors (Griffin) | 1.35M | -49% | $76M | 0.04% |
| D.E. Shaw | 525.1K | -53% | $29M | 0.02% |
| Point72 (Cohen) | 106.5K | -78% | $6.0M | 0.01% |
| Millennium Mgmt (Englander) | 12.0K | $700.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 2.99% of its shares outstanding were held short, -0.3% since the report before.
- Shares held short
- 12.84M
- 2.99%
- Since the report before12.89M on Sep 30, 2026
- -0.3%
- 4.3
- 3.00M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 52%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 10.97M
- Nov 15, 2023: Shares held short 9.83M
- Nov 30, 2023: Shares held short 10.01M
- Dec 15, 2023: Shares held short 12.34M
- Dec 29, 2023: Shares held short 11.21M
- Jan 12, 2024: Shares held short 10.19M
- Jan 31, 2024: Shares held short 10.28M
- Feb 15, 2024: Shares held short 11.50M
- Feb 29, 2024: Shares held short 13.13M
- Mar 15, 2024: Shares held short 12.65M
- Mar 28, 2024: Shares held short 12.39M
- Apr 15, 2024: Shares held short 14.15M
- Apr 30, 2024: Shares held short 13.75M
- May 15, 2024: Shares held short 13.28M
- May 31, 2024: Shares held short 13.25M
- Jun 14, 2024: Shares held short 15.54M
- Jun 28, 2024: Shares held short 16.90M
- Jul 15, 2024: Shares held short 16.49M
- Jul 31, 2024: Shares held short 14.87M
- Aug 15, 2024: Shares held short 14.28M
- Aug 30, 2024: Shares held short 14.68M
- Sep 13, 2024: Shares held short 14.19M
- Sep 30, 2024: Shares held short 14.57M
- Oct 15, 2024: Shares held short 14.46M
- Oct 31, 2024: Shares held short 14.55M
- Nov 15, 2024: Shares held short 14.67M
- Nov 29, 2024: Shares held short 15.70M
- Dec 13, 2024: Shares held short 15.65M
- Dec 31, 2024: Shares held short 16.56M
- Jan 15, 2025: Shares held short 16.63M
- Jan 31, 2025: Shares held short 16.13M
- Feb 14, 2025: Shares held short 15.30M
- Feb 28, 2025: Shares held short 13.75M
- Mar 14, 2025: Shares held short 15.57M
- Mar 31, 2025: Shares held short 18.01M
- Apr 15, 2025: Shares held short 20.57M
- Apr 30, 2025: Shares held short 18.59M
- May 15, 2025: Shares held short 20.74M
- May 30, 2025: Shares held short 29.02M
- Jun 13, 2025: Shares held short 29.03M
- Jun 30, 2025: Shares held short 16.91M
- Jul 15, 2025: Shares held short 16.73M
- Jul 31, 2025: Shares held short 15.18M
- Aug 15, 2025: Shares held short 14.07M
- Aug 29, 2025: Shares held short 16.62M
- Sep 15, 2025: Shares held short 21.28M
- Sep 30, 2025: Shares held short 12.87M
- Oct 15, 2025: Shares held short 13.58M
- Oct 31, 2025: Shares held short 14.19M
- Nov 14, 2025: Shares held short 24.03M
- Nov 28, 2025: Shares held short 24.33M
- Dec 15, 2025: Shares held short 27.72M
- Dec 31, 2025: Shares held short 28.80M
- Jan 15, 2026: Shares held short 27.51M
- Jan 30, 2026: Shares held short 26.46M
- Feb 13, 2026: Shares held short 13.44M
- Feb 27, 2026: Shares held short 12.16M
- Mar 13, 2026: Shares held short 11.58M
- Mar 31, 2026: Shares held short 11.52M
- Apr 15, 2026: Shares held short 12.01M
- Apr 30, 2026: Shares held short 13.82M
- May 15, 2026: Shares held short 12.68M
- May 29, 2026: Shares held short 11.59M
- Jun 15, 2026: Shares held short 11.13M
- Jun 30, 2026: Shares held short 12.44M
- Jul 15, 2026: Shares held short 12.13M
- Jul 31, 2026: Shares held short 10.67M
- Aug 14, 2026: Shares held short 11.61M
- Aug 31, 2026: Shares held short 11.90M
- Sep 15, 2026: Shares held short 11.65M
- Sep 30, 2026: Shares held short 12.89M
- Oct 15, 2026: Shares held short 12.84M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading44.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 44.2% of the shares in the reported trades were short sales, against 47.2% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 44.2%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 47.2%
- Change
- -3.0 pts
- Short sales a dayon average, of 1.48M shares
- 656.0K
- More than atof 3,656 US-listed companies, same days
- 30%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 48.1%
- Oct 13, 2026: Short sales 51.2%
- Oct 14, 2026: Short sales 32.7%
- Oct 15, 2026: Short sales 52.2%
- Oct 16, 2026: Short sales 44.8%
- Oct 19, 2026: Short sales 44.5%
- Oct 20, 2026: Short sales 55.7%
- Oct 21, 2026: Short sales 44.4%
- Oct 22, 2026: Short sales 54.8%
- Oct 23, 2026: Short sales 54.2%
- Oct 26, 2026: Short sales 50.3%
- Oct 27, 2026: Short sales 49.9%
- Oct 28, 2026: Short sales 47.9%
- Oct 29, 2026: Short sales 31.4%
- Oct 30, 2026: Short sales 45.6%
- Nov 2, 2026: Short sales 55.8%
- Nov 3, 2026: Short sales 59.9%
- Nov 4, 2026: Short sales 56.3%
- Nov 5, 2026: Short sales 53.5%
- Nov 6, 2026: Short sales 45.3%
- Nov 9, 2026: Short sales 42.5%
- Nov 10, 2026: Short sales 42.9%
- Nov 11, 2026: Short sales 31.5%
- Nov 12, 2026: Short sales 28.4%
- Nov 13, 2026: Short sales 34.1%
- Nov 16, 2026: Short sales 35.4%
- Nov 17, 2026: Short sales 37.2%
- Nov 18, 2026: Short sales 43.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Pablo G. LegorretaCEO, Chairman of the BoardDirectly4.95M
- Christopher HiteEVP & Chairman, PartneringDirectly200.7K
- Gregory NordenDirectorDirectly196.3K
- Marshall UristEVP, Research & InvestmentsDirectly149.4K
- Bonnie L BasslerDirectorDirectly79.8K
- Ted W LoveDirectorDirectly58.4K
- Catherine M. EngelbertDirectorDirectly55.7K
- Terrance P. CoyneEVP & CFODirectly50.4K
- David C HodgsonDirectorDirectly37.9K
- Vlad CoricDirectorDirectly15.3K
- Elizabeth H WeathermanDirectorDirectly13.1K
- Carole HoDirectorDirectly13.1K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Pablo G. LegorretaCEO, Chairman of the Board | 4.95M | – | Nov 4, 2026 | Form 4 |
| Christopher HiteEVP & Chairman, Partnering | 200.7K | – | Nov 17, 2026 | Form 4 |
| Gregory NordenDirector | 196.3K | – | Jun 5, 2026 | Form 4 |
| Marshall UristEVP, Research & Investments | 149.4K | – | Nov 16, 2026 | Form 4 |
| Bonnie L BasslerDirector | 79.8K | – | Sep 30, 2026 | Form 4 |
| Ted W LoveDirector | 58.4K | – | Jun 5, 2026 | Form 4 |
| Catherine M. EngelbertDirector | 55.7K | – | Jun 5, 2026 | Form 4 |
| Terrance P. CoyneEVP & CFO | 50.4K | – | Nov 17, 2026 | Form 4 |
| David C HodgsonDirector | 37.9K | – | Jun 5, 2026 | Form 4 |
| Vlad CoricDirector | 15.3K | – | Jun 5, 2026 | Form 4 |
| Elizabeth H WeathermanDirector | 13.1K | – | Jun 5, 2026 | Form 4 |
| Carole HoDirector | 13.1K | – | Jun 5, 2026 | Form 4 |
A lower bound: it counts only the 12 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund4.33%
- VFLOVictoryShares Free Cash Flow ETFWeight in the fund1.76%
- SCHMSchwab U.S. Mid-Cap ETFWeight in the fund0.45%
- IYHiShares U.S. Healthcare ETFWeight in the fund0.40%
- FNDASchwab Fundamental U.S. Small Company ETFWeight in the fund0.32%
- VLUEiShares MSCI USA Value Factor ETFWeight in the fund0.27%
- JQUAJPMorgan U.S. Quality Factor ETFWeight in the fund0.26%
- VXFVanguard Extended Market Index FundWeight in the fund0.26%
- GSLCGoldman Sachs ActiveBeta(R) U.S. Large Cap Equity ETFWeight in the fund0.24%
- IWSiShares Russell Mid-Cap Value ETFWeight in the fund0.23%
33 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 489
- Q4 2025: Managers 540
- Q1 2026: Managers 594
- Q2 2026: Managers 645
Institutional investors by quarter
The fund managers holding RPRX, quarter by quarter, from Q1 2013 to Q2 2025, 47 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 645 managers held 367M shares, worth $20.5B. During the quarter 105 opened a position, 54 closed one, 288 added and 174 trimmed.
The largest holders, Q2 2026
- Morgan StanleyIn the quarter-1.5%
- Capital International InvestorsIn the quarter+0.8%
- BlackRockIn the quarter+7.4%
- FMRIn the quarter-2.5%
- State StreetIn the quarter+12%
- Price T Rowe AssociatesIn the quarter+479%
- Swedbank ABIn the quarter-7.4%
- Baillie GiffordIn the quarter-38%
- Capital World InvestorsIn the quarter+18%
- Geode Capital ManagementIn the quarter+2.4%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Morgan Stanley | 42.93M | -1.5% | $2.4B |
| Capital International Investors | 35.27M | +0.8% | $2.0B |
| BlackRock | 27.83M | +7.4% | $1.6B |
| FMR | 24.51M | -2.5% | $1.4B |
| State Street | 12.34M | +12% | $692M |
| Price T Rowe Associates | 11.19M | +479% | $628M |
| Swedbank AB | 10.73M | -7.4% | $601M |
| Baillie Gifford | 10.02M | -38% | $562M |
| Capital World Investors | 9.52M | +18% | $534M |
| Geode Capital Management | 8.06M | +2.4% | $451M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Royalty Pharma's filings show?
Who buys and sells is one part of Royalty Pharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have RPRX's insiders bought or sold?
From May 28, 2026 to Nov 18, 2026 Royalty Pharma's insiders bought 0 and sold $59M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold RPRX?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $241M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.